Drug intelligence / Profile preview

Ebola virus vaccine

Development stage: Unknown
Lead developer: Merck
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular, Oral, Intranasal, Intratracheal, Inhalation

Overview

This Ebola virus vaccine candidate was developed by a public-private consortium including the University of Maryland School of Medicine (UM SOM), Paragon Bioservices, the National Institute of Allergy and Infectious Diseases (NIAID), and GSK in response to the 2014 Ebola outbreak. It utilizes a recombinant adenovirus platform to express an Ebola virus glycoprotein, aiming to induce an immune response against the virus. The vaccine entered Phase 1 clinical trials in the U.S., UK, and West Africa in late 2014.

Targets

Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on Ebola virus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ebola virus vaccine.

Explore the full profile